Category: Clinical Trial Update Region: Europe · United Kingdom Company: Storm Therapeutics Ltd

STORM Therapeutics begins patient dosing in phase 1 study of oral METTL3 inhibitor, STC-15 to treat solid tumour

By, Admin 1 min read
Share
STORM Therapeutics begins patient dosing in phase 1 study of oral METTL3 inhibitor, STC-15 to treat solid tumour
STORM Therapeutics Ltd., a biotechnology company, announces that the first patient has been dosed with STC-15, the company

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!